Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$3.93 USD
-0.01 (-0.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.92 -0.01 (-0.25%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ALDX 3.93 -0.01(-0.25%)
Will ALDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Other News for ALDX
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics Unveils R&D Progress and Goals
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 15.5% Annualized Using Options
Fly Insider: Xilio, Aerovate among week���s notable insider trades